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Abstract
Introduction: Acute stroke unit care, intravenous thrombolysis and endovascular treatment significantly improve the
outcome for patients with ischaemic stroke, but data on access and delivery throughout Europe are lacking. We assessed
best available data on access and delivery of acute stroke unit care, intravenous thrombolysis and endovascular treat-
ment throughout Europe.
Methods: A survey, drafted by stroke professionals (ESO, ESMINT, EAN) and a patient organisation (SAFE), was sent to
national stroke societies and experts in 51 European countries (World Health Organization definition) requesting
experts to provide national data on stroke unit, intravenous thrombolysis and endovascular treatment rates. We
compared both pooled and individual national data per one million inhabitants and per 1000 annual incident ischaemic
strokes with highest country rates. Population estimates were based on United Nations data, stroke incidences on the
Global Burden of Disease Report.
Results: We obtained data from 44 European countries. The estimated mean number of stroke units was 2.9 per
million inhabitants (95% CI 2.3–3.6) and 1.5 per 1000 annual incident strokes (95% CI 1.1–1.9), highest country rates
were 9.2 and 5.8. Intravenous thrombolysis was provided in 42/44 countries. The estimated mean annual number of
intravenous thrombolysis was 142.0 per million inhabitants (95% CI 107.4–176.7) and 72.7 per 1000 annual incident
strokes (95% CI 54.2–91.2), highest country rates were 412.2 and 205.5. Endovascular treatment was provided in 40/44
countries. The estimated mean annual number of endovascular treatments was 37.1 per million inhabitants (95% CI
26.7–47.5) and 19.3 per 1000 annual incident strokes (95% CI 13.5–25.1), highest country rates were 111.5 and 55.9.
Overall, 7.3% of incident ischaemic stroke patients received intravenous thrombolysis (95% CI 5.4–9.1) and 1.9%
received endovascular treatment (95% CI 1.3–2.5), highest country rates were 20.6% and 5.6%.
Conclusion: We observed major inequalities in acute stroke treatment between and within 44 European countries.
Our data will assist decision makers implementing tailored stroke care programmes for reducing stroke-related mor-
bidity and mortality in Europe.
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Introduction
Stroke is the second most common single cause of
death in Europe. It is responsible for more than one
million deaths per year and is the leading cause of long-
term disability.1,2 Twenty to 35% of stroke patients die
within the first month after a stroke, and up to one-
third of survivors lose their independence.3,4,5
Consequently, the socioeconomic impact of stroke is
considerable: the annual cost of stroke in Europe is
estimated to be e45 billion: e20 billion for direct care,
e9 billion related to loss of productivity and e16 billion
for informal care.1 The burden of stroke differs widely
across Europe. Specifically, the incidence and case
fatality of stroke in central and eastern European coun-
tries remain higher than in northern, western and
southern European countries.1,6–9
The main pillars of acute ischaemic stroke treatment
are stroke unit (SU) care and treatments promoting
revascularisation. SUs, defined as dedicated areas or
wards in hospitals open round the clock, where stroke
patients are admitted and cared for by a multidiscipli-
nary team including medical, nursing and therapy staff,
are most effective in reducing mortality and morbidi-
ty.10–12 Since 2002, intravenous thrombolysis (IVT) has
been approved in Europe for use in acute stroke treat-
ment.13 In 2015, following randomised controlled trials
demonstrating that endovascular treatment (EVT) dra-
matically improves the outcome of stroke patients with
large vessel occlusion in the anterior circulation,
European guidelines recommended the use of EVT in
comprehensive stroke centres (CSCs).14–16 However,
pan-European data on the access to and delivery of
SU care, IVT and EVT are lacking.
Therefore, the European Stroke Organisation
(ESO), the European Society of Minimally Invasive
Neurological Therapy (ESMINT), the European
Academy of Neurology (EAN) and the Stroke
Alliance for Europe (SAFE) surveyed the access to
and delivery rates of acute SU care, IVT and EVT
throughout Europe.
Objectives
We aimed to collect national data on access to and
delivery rates for acute SU care, IVT and EVT
throughout Europe. We compared both pooled data
of all countries and individual country rates with high-
est country rates. We also aimed to estimate the
number of SUs necessary to cover the needs of the
European population and to calculate how many
patients could be treated with IVT and EVT if best
practice were to be followed in all European countries.
Methods
Study design and participants
This pan-European study surveyed European chairs of
national stroke societies and stroke experts on the
access to and delivery rates of acute SU care, IVT
and EVT in their countries. The study’s steering com-
mittee consisted of 10 representatives from ESO,
ESMINT, EAN and SAFE, including at least 1
board member from each society. The survey was
pre-announced six months before it started in the
ESO, ESMINT, and EAN newsletters. The World
Health Organization (WHO)’s definition of the
European region as including 51 countries was
adopted. Countries with less than 100,000 inhabitants
(Monaco, Liechtenstein, Andorra, and San Marino)
were excluded, and North Cyprus, which was not
listed under the WHO definition, was added.
National stroke society chairs were invited to be coun-
try coordinators by the steering committee. In the
absence of a national stroke or neurological society,
national coordinators were selected by the steering
committee, following a thorough review of proposals
proffered by board members and/or country represen-
tatives of ESO, EAN or ESMINT. Each country coor-
dinator was responsible for selecting two additional
national stroke experts, one of whom was a neuroin-
terventionalist, whenever possible. Coordinators and
experts were responsible for identifying the most reli-
able and most recent national data sources (i.e. stroke
registries, governmental data sources, etc.) to answer
the survey questions. In the absence of national or
local stroke registries, the coordinator and experts
were asked to perform best estimates by consensus,
and took full responsibility for the validity of the
responses provided. The affiliations of the 44 coordina-
tors and 58 experts are shown in Supplementary
Appendix 1.
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Data collection
The survey was drafted by the steering committee after a
series of meetings, audio conferences and e-mail corre-
spondence. Thereafter, it was externally reviewed by
four stroke experts with extensive research skills and
proven experience in drafting European stroke
surveys (see Acknowledgments and Supplementary
Appendix 1). The survey consisted of 64 items
(Supplementary Appendix 2). The first section collected
information on the professional background of the
coordinators and experts. Subsequent sections dealt
with stroke care and prehospital stroke care pathways,
acute stroke treatment strategies, information on stroke
registries and quality control, as well as stroke aware-
ness campaigns. The definition of an acute SUwas based
on local and/or national definitions. A pilot survey was
performed in Austria, Hungary, Poland, Spain and
Switzerland to assess feasibility. The survey was per-
formed between 30 October 2016 and 24 February
2017. Collected data were independently reviewed by
two authors (RVM, DAS). Whenever there was ambi-
guity and/or missing or conflicting responses, the steer-
ing committee requested clarifications, and final
approvals were granted by the steering committee.
Data analyses
Our analyses focused on access to and delivery rates of
acute SU care, IVT and EVT as well as the number
of centres delivering IVT and EVT. All data were
analysed using appropriate descriptive methods.
Whenever a response was ‘unknown’, it was eliminated.
We calculated crude rates of acute SUs per one million
inhabitants using United Nations population estimates
(2015 Revision of World Population Prospects),17 with
the exception of Serbia, for which estimates from the
Statistical Office of the Republic of Serbia were used
(not including Kosovo and Metohija). Similar calcula-
tions were done for annual numbers of IVT and EVT
performed, and number of centres providing IVT and
EVT within each country. The annual incidence of
ischaemic stroke per country was based on the esti-
mates from the Global Burden of Disease Report
(2016).8 These data were used to test the associations
between SUs, IVT and EVT rates per million popula-
tion using Pearson correlation. We calculated the
number of acute SUs necessary to reach the defined
target of three acute SUs per one million inhabitants
or one SU per 1000 annual incident strokes.18,19 We
also calculated how many additional patients could
be treated if an IVT rate of 18% could be achieved in
all countries, and similar calculations were done for
patients treated with EVT if an EVT rate of 5%
could be achieved in all countries. Both cut-offs were
data driven and were based on the next lower whole-
numbered value of the three countries with highest
rates. The data obtained from the survey were collated
and analysed in Microsoft Excel, version 2010
(Microsoft Corporation, Redmond, WA, USA).
Selected variables were imported into Stata 14
(StataCorp, College Station, TX, USA) for fur-
ther analysis.
Best practice
We compared both pooled and individual national
data per one million inhabitants and per annual inci-
dent ischaemic stroke rates regarding access to and
delivery of SU care and IVT and EVT therapies with
highest country rates.
Patient involvement
A representative from a patient organisation (SAFE)
was involved in all stages of the research project (i.e.
generating hypothesis, design of the survey, interpreta-
tion of the results and critical revision of the manu-
script). This patient representation is intended to
insure sufficient integration of the patient perspective,
and better dissemination of results to patients and next
of kin.
Results
Overall, 44/51 invited countries participated
(Supplementary Figure 1). Seven countries did not
respond to multiple attempts at contact. The total
number of inhabitants in the 44 participating countries
was estimated to be 835 million.17 Overall, 22 (50%)
surveys were completed by a coordinator and two
experts, 9 (20%) by a coordinator and one expert,
and 13 (30%) by a coordinator alone.
Acute SUs, IVT hospitals and EVT centres
Information on acute SU care was provided for 42/44
countries. National requirements for SUs were defined
in 29 countries (68%) and planned in seven countries
(16%) (Supplementary Figure 2). Overall, there were
2139 acute SUs in 42 countries, corresponding to a
pooled mean of 2.9 SUs per million inhabitants (95%
CI; 2.3–3.6) (Table 1, Supplementary Figure 3) and 1.5
(95% CI; 1.1–1.9) per 1000 annual incident ischaemic
strokes (Table 2, Supplementary Figure 6). There was a
considerable heterogeneity among the 42 countries
(Figures 1 and 2). Countries with highest rates had
9.2 acute SUs per one million population and 5.8 per
1000 annual incident ischaemic strokes. Ten countries
had less than one acute SU per one million inhabitants.
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Overall, 43/44 countries reported the number of hos-
pitals delivering IVT (Table 1). IVT was performed at
2282 hospitals, corresponding to a mean number of
3.6 (95% CI; 2.7–4.4) IVT hospitals per one million
inhabitants and 1.9 (95% CI; 1.3–2.5) per 1000
annual incident ischaemic strokes. Countries with
highest rates had 15.2 IVT hospitals per one million
population and 11.9 per 1000 annual incident ischae-
mic strokes.
All countries reported the number of centres deliv-
ering EVT (Table 1). EVT was performed at 629 stroke
centres, corresponding to a mean number of 0.9 (95%
CI; 0.6–1.2) EVT centres per one million inhabitants
and 0.4 (95% CI; 0.3–0.5) per 1000 annual incident
ischaemic strokes (Table 2). Countries with highest
rates had 6.4 EVT centres per one million population
and 1.9 per 1000 annual incident ischaemic strokes.
Twenty-nine countries had less than one stroke centre
capable of performing EVT per one million inhabi-
tants. Centres offering EVT round the clock were pro-
vided by 33 countries (Table 1). According to
coordinators and experts, the available centres met
the needs for EVT in 15/43 countries. In eight of the
countries currently lacking full EVT coverage, it was
already being planned. In the remaining 20 countries,
there were no plans to provide full national access to
EVT in the near future. National protocols for EVT
were available in 20 countries (Supplementary Table 1
and 2).
IVT
Overall, 43/44 countries provided figures on annual
IVTs performed. IVT was not available in 2/44 coun-
tries. The number of IVTs performed came from
national IVT registries in 26 countries. The remaining
countries provided data from national offices of statis-
tics, service reports or estimates made by coordinators
and experts. For all countries, data were from the years
2015 or 2016 (Tables 1 and 2).
Overall, the total annual number of patients receiv-
ing IVT in 43 countries was 113,267. The estimated
mean number of IVTs per one million inhabitants for
these 43 countries was 142.0 (95% CI; 107.4–176.7) and
72.7 (95% CI; 54.2–91.2) per 1000 annual incident
ischaemic strokes, while the highest country rates
were 412.2 and 205.5, respectively (Supplementary
Figure 4). In 10 countries, the estimated annual num-
bers of IVT treatments delivered per one million inhab-
itants were fewer than 50, whereas four countries had
rates above 350 (Figure 3). Overall, 7.3% (95% CI;
5.4–9.1) of all patients with an ischaemic stroke in
Europe received IVT, whereas 13 countries reported
IVT rates of 10% or more (Table 2, Figure 4,
Supplementary Figure 7).
The two most frequent reasons for not performing
IVT were late patient admission (27 countries) and a
lack of personnel with stroke expertise on site (15 coun-
tries). Other reasons included a lack of immediate
Figure 1. Choropleth map showing number of stroke units per million population in 42 European countries (mean 2.9, 95% CI
2.3–3.6).
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access to brain imaging (5 countries), and a lack of a
round the clock SU and/or medical laboratory avail-
ability in five countries. In Kyrgyzstan, alteplase was
scheduled to be approved for the treatment of acute
ischaemic stroke treatment in the near future. The
cost was singled out as a barrier to providing IVT in
four countries. The number of acute SUs per one mil-
lion population was significantly associated with the
Figure 2. Choropleth map showing number of stroke units per 1000 annual incident ischaemic strokes in 42 European countries
(mean 1.5; 95% CI 1.1–1.9).
Figure 3. Choropleth map showing contemporary annual rates of intravenous thrombolysis (IVT) per million population in 42
European countries (mean 142.0, 95% CI 107.4–176.7).
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number of IVTs delivered per million population
(Pearson correlation coefficient 0.54, p¼ 0.0002)
(Supplementary Figure 9).
EVT
EVT was available in 40/44 countries and 39 countries
provided figures on annual numbers of EVTs per-
formed. The number of EVTs performed came from
national registries in 14 countries. The remaining coun-
tries provided data from national offices of statistics,
service reports, extrapolation from locally obtained fig-
ures or estimates by coordinators and experts. For
most countries, data were from 2016 (Tables 1 and 2).
Overall, 27,505 procedures were performed, corre-
sponding to a mean number of 37.1 procedures per
one million inhabitants (95% CI; 26.7–47.5) and 19.3
(95% CI; 13.5–25.1) per 1000 annual incident ischae-
mic strokes, while highest country rates were 111.5 and
55.9, respectively (Supplementary Figure 5 and 8). The
annual number of treatments delivered per million
inhabitants was fewer than 10 per one million inhabi-
tants in 13 countries, whereas three countries reported
EVT rates above 100 per one million (Table 1,
Figure 5). Overall, 1.9% (95% CI; 1.3–2.5) of all
patients with an ischaemic stroke in Europe received
EVT, 15 countries reported EVT rates of 3% or more
(Table 2, Figure 6).
The most common reasons reported for not provid-
ing EVT to all eligible patients were lack of specifically
trained personnel (34 countries), lack of facilities
(22 countries) and costs (16 countries). Overall, we
observed that the number of EVTs delivered per one
million population tended to be higher in countries
with a greater number of SUs (Pearson correlation
coefficient 0.36, p¼ 0.02).
Discussion
Our study shows that (1) for most European countries,
access to and delivery of SUs, IVT and EVT are far
below highest country rates and there are considerable
inequalities among and within the different countries,
(2) only 7.3% of all acute ischaemic stroke patients
receive IVT and only 1.9% receive EVT, (3) and
there is a significant correlation between the number
of SUs per million inhabitants and delivery rates for
both IVT and EVT.
Although there has been a dense network of SUs in
northern European countries for the past two decades,
no such network is present in most eastern and south-
ern European countries. The European Brain Council
has recently estimated that only one in three stroke
patients in Europe has access to acute SU care.19 We
have calculated that, in order to provide three SUs per
one million inhabitants across Europe, at least 628
additional SUs would be needed in 20 countries
(Table 3), and in order to reach one SU per 1000
annual incident ischaemic strokes, 447 SUs would be
necessary in 18 countries. However, these calculations
are rough estimates, based on the assumption that
Figure 4. Choropleth map showing contemporary annual estimates of the proportion of patients with incident ischaemic stroke
treated with intravenous thrombolysis (IVT) in 42 European countries (mean 7.3%; 95% CI 5.4–9.1).
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Table 3. Estimated number of additional stroke units and comprehensive stroke centres required to achieve three stroke units per
one million inhabitants and one comprehensive stroke centre per one million inhabitants, and estimated number of additional
treatments with intravenous thrombolysis and endovascular interventions if rates of 18% and 5%, respectively, are to be achieved.
Country
No. of
additional
stroke units
required
No. of
additional
comprehensive
stroke centres
required
No. of
additional
intravenous thrombolysis
treatments per year
(target rate 18%)
No. of
additional endovascular
treatments per year
(target rate 5%)
Albania 8 2 867 235
Austria 0 0 0 166
Belarus – 8 – –
Belgium – 0 1294 278
Bosnia and Herzegovina 7 3 2294 629
Bulgaria 0 3 4900 1409
Croatia 0 2 3350 984
Czech Republic 0 0 1758 481
Denmark 0 3 0 137
Estonia 0 0 135 79
Finland 0 1 683 227
France 53 27 7727 0
Georgia 10 4 1611 449
Germany 0 0 924 0
Greece 28 5 3768 1069
Hungary 0 4 3820 1352
Iceland 0 0 45 21
Ireland 0 3 316 30
Israel 14 0 134 71
Italy 1 10 11,586 3559
Kyrgyzstan 13 6 943 262
Latvia 0 0 1311 419
Lithuania 1 0 1558 351
Luxembourg 0 0 96 32
FYROM 5 1 1009 295
Malta 0 0 57 0
Montenegro 2 1 217 66
Netherlands 0 0 0 85
Northern Cyprus 0 0 – –
Norway 0 0 381 262
Poland 0 18 11,398 4795
Portugal 6 1 1761 65
Republic of Moldova 10 4 1682 460
Romania 49 18 14,064 3947
Russia 0 9 85,366a 26,689a
Serbia 11 3 5294 1572
Slovakia 0 0 1957 429
Slovenia 3 1 433 89
Spain 78 9 6985 922
Sweden 0 4 525 478
Switzerland 2 0 1321 19
Turkey 203 58 10,952 2997
Ukraine 124 41 28,663 8035
United Kingdom 0 37 5477 3902
Total 628 286 226,662 67,347
FYROM: former Yugoslav Republic of Macedonia.
aAccording to the local experts, the incidence of ischemic stroke is overestimated.
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existing SUs are equally distributed within countries
and that there is a uniform population distribution
throughout Europe. In remote rural areas, more SUs
might be necessary to meet the needs of the population,
whereas in urban areas, high volume SUs can care for
more stroke patients. Furthermore, we did not take
into consideration the number of beds in the SUs and
some SUs are likely to be too small to meet the needs of
patients in their area. In line with the results regarding
the availability of SUs, the number of EVT centres per
Figure 5. Choropleth map showing contemporary annual rates of endovascular treatments (EVT) for ischaemic stroke per million
population in 43 European countries (mean 37.1, 95% CI 26.7–47.5).
Figure 6. Choropleth map showing contemporary annual estimates of the proportion of patients with incident ischaemic stroke
receiving endovascular treatment (EVT) in 42 European countries (mean 1.9%; 95% CI 1.3–2.5).
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country also varies significantly throughout Europe;
28 countries did not reach the benchmark of one
CSC per one million inhabitants.20 To achieve this
goal, at least 286 more CSCs delivering EVT would
be needed in these 28 countries (Table 3). It is also
noteworthy that some countries, as Albania, Bulgaria,
Greece, Luxembourg, FYROM, Romania, Russia,
Serbia and Ukraine, had a very low mean annual
number of EVT per CSC. Although we recognise that
in some cases this might be accounted by a low but
growing case volume in recently created centres in
2016, which was a year of change in many countries
regarding the organisation of EVT centres, this also
indicates the need to implement basic requirements
for CSC.
Governments, health care professionals and stroke
specialists should now carefully plan and implement
networks of SUs providing IVT and CSCs delivering
EVT, taking into account geographical conditions and
regional and local characteristics while still being
affordable. CSCs will require round the clock stroke
physicians with expertise in endovascular stroke man-
agement, and fully trained neurointerventionalists with
qualifications based on current models of certifica-
tion.21,22 Too many competing EVT centres will not
be cost-effective, will compromise quality and will
dilute the expertise of specialists. Universal adoption
of a uniform definition of SUs and CSCs together
with an appropriate certification process would help
to guarantee the achievement of set quality targets
throughout Europe.
IVT and EVT
Overall, 7.3% of all patients received IVT and 1.9%
EVT. So far, population-based studies on IVT and
EVT rates are scarce and there are no established and
well-accepted benchmarks for determining what pro-
portion of patients with acute ischaemic stroke
should receive IVT and EVT. The burden of stroke
report provided thrombolysis rates in national and
large regional audits, but the denominator of popula-
tions varied between ‘all stroke patients’, ‘all ischaemic
stroke patients’, ‘hospitalised stroke patients’, ‘stroke
unit patients’ and others, making reliable comparisons
impossible.9 Furthermore, using hospitalised stroke
patients as the denominator can be misleading, since
hospitalisation rates for stroke vary across Europe.9 In
the same report, average annual thrombolysis rates per
100,000 population were only provided for 11 coun-
tries, within different time frames. The denominators
of our survey were the population at risk and the
number of incident ischaemic strokes, based on the
2015 Global Burden of Disease Report.8 Highest prac-
tice rate for IVT was 20.6%, whereas 13 countries had
IVT rates of 10% or more. Highest EVT rates were
5%, with 15 countries achieving 3% or more.
The estimated number of additional patients who
could be treated with IVT taking 18% as the threshold
is 226,662, and the estimated number of additional
patients who could be treated with EVT at a threshold
of 5% is 67,347 (Table 3). However, these are still
rather conservative estimates, since even the IVT and
EVT rates in countries with the highest rates can be
improved. In Germany, for instance, only 60% of eli-
gible patients were reported to have been treated by
IVT in 2012.9 Based on the available evidence from
intervention trials and prospective registries for EVT,
a recent study in the UK has estimated that approxi-
mately 10% of stroke patients admitted to hospital
were eligible for EVT.23
Implications
Our findings have implications for the future organisa-
tion of acute stroke care in Europe as we have shown in
which countries rates of SUs, IVT and EVT are cur-
rently below best practice. In 2006, the second
Helsingborg Declaration, co-sponsored by the WHO
Regional Office for Europe, set new targets for stroke
management and care.24 One specific goal for 2015 was
that all patients with acute stroke who were potentially
eligible for acute, specific treatment, were transferred to
hospitals with adequate capacity and expertise to
administer treatments – defined as a SU or stroke ded-
icated area. Our survey shows that many patients still
have no access to appropriate acute stroke treatment
and a clear action plan to address these inequalities is
urgently needed. Therefore, a third Action Plan for
Stroke in Europe is currently being drafted to set
achievement goals for 2030 and the present survey
will provide important information for future health
care planning. By increasing the awareness of what
needs to change, this knowledge may also be useful
for local and national stroke patient and professional
organisations, in order to develop tailored approaches
that consider the specific barriers faced by national
healthcare systems and take the first vital steps to
improve overall stroke care. To develop a successful
strategy for change, you need to understand the types
of barriers faced in healthcare. Using this data, you can
consider which barriers and levers may operate in your
organisation and which may be relevant to a particular
problem. Following careful analysis, it is possible to
develop a tailored approach to overcome the barriers,
encourage changes in behaviour and ultimately imple-
ment guidance.
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Strengths and limitations
A major strength of our survey – apart from the large
number of participating countries – is that data were
mostly based on national stroke registries.
Furthermore, the survey questions were answered by
experienced stroke and neurointerventional experts.
Our survey does, however, have several important lim-
itations: (1) The population density is not reflected in
the survey owing to the lack of well-established indica-
tors for each individual European country. (2) Several
countries lack prospective stroke registries and coordi-
nators and experts had to use multiple sources of
regional and local information to extrapolate national
figures. (3) Given the lack of a uniform definition of
SUs, some differences in SU rates are likely to be relat-
ed to differences in definitions. Furthermore, we did
not assess the number of patients treated in SUs. (4)
Estimated stroke incidence rates of the 2015 Global
Burden of Disease Report – the most accepted global
data on stroke incidence – might eventually be too high
for some countries, while for other countries, rates
might be too low. We have therefore presented data
both ways, per one million inhabitants and per 1000
annual incident ischaemic strokes. Finally, the methods
used to collect information in countries lacking nation-
al stroke registries were not standardised and therefore
in these cases, data should be seen as exploratory. The
development of stroke registries, internal and external
audits in those countries should be a goal, in order to
improve the quality of data gathered. However, since in
most cases this is not expected to happen in the near
future, we do believe that communication of those pre-
liminary results provides the opportunity to highlight
the need for change and can lead to effective results.
Conclusions
This is the first comprehensive survey on access to and
delivery rates of acute SU care, IVT and EVT in
Europe. We found major inequalities in treatment of
acute stroke patients between and within 44 European
countries, and in many countries rates are far below
highest country rates, leaving many patients untreated.
Individual country level data indicate where access to
and delivery of acute stroke care is insufficient or lack-
ing and allows comparison with highest country rates.
These data will support governments, health care pro-
viders and European politicians to draw up action
plans to implement acute stroke treatment, tailored
for each European country, in order to reduce stroke-
related mortality and morbidity in Europe.
“ESO ESMINT EAN SAFE Survey on Stroke Care
in Europe” collaborators
MPetrela, O Taka, E Enesi (Albania); S Kiechl, M Brainin, F
Fazekas (Austria); P Konovalov (Belarus); A Peeters, G
Vanhooren, L Defreyne (Belgium); H Haris, M Moranjkic
(Bosnia and Herzegovina); S Andonova, I Staikov
(Bulgaria); H Budincevic, D Ozretic, B Malojcic (Croatia);
A Tomek (Czech Republic); H Iversen, SP Jonhsen
(Denmark); J Korv, R Vibo, V Malikov (Estonia); T
Sairanen, D Strbian, K Lappalainen (Finland); S Timsit, E
Touze, D Leys (France); A Tsiskaridze, I Burduladze
(Georgia); M Dichgans, J R€other, J Fiehler (Germany); G
Tsivgoulis, E Brountzos (Greece); D Bereczki. C O´va´ry, I
Szikora (Hungary); B Thorarinsson, V Vilmarsson
(Iceland); J Harbison (Ireland); N Bornstein, D Tanne, A
Horev (Israel); D Toni, S Mangiafico, V Caso (Italy); A
Murzaliev, I Lutsenko, A Artykbaev, (Kyrgyzstan); E
Migl~ane, K Kupcs, I Kikule (Latvia); D Jatuzis, D
Rastenyte, M Kurminas (Lithuania); D Ulbricht
(Luxembourg); A Arsovska, M Smiceska, E Lickova (The
former Yugoslav Republic of Macedonia); M Mallia, R
Grech, M Schembri (Malta); V Lisnic, E Manole, E Zota
(Moldova); M Cukic (Montenegro); D Dippel, C Majoie, H
B van der Worp (Netherlands); S Akpinar (Northern
Cyprus); E Berge, Hanne Ellekjær (Norway); A
Czlonkowska, W Poncyljusz, A Kobayashi (Poland); E
Azevedo, V Tedim-Cruz, M Ribeiro (Portugal); C Tiu
(Romania); T Kharitonova (Russia); L Bumbasirevic
(Serbia); Z Gdovinova, I Vulev, P Turcani (Slovakia); B
Zvan, V Svigelj, Z Milosevic (Slovenia); J Ga´llego, M
Rodrıguez Ya´~nez, E Palacio-Portilla, A Gonzallez Mandly,
M Gallofre´, S Abilleira, C Gimenez, S Calleja-Puerta, J
Marta-Moreno, M O´scar Ayo, A Lago (Spain); M Arnold
(Switzerland); M Mazya, T Moreira (Sweden); N Uzuner, L
Gungor, O Ozdemir (Turkey); H Rodgers, J Dawson, P
White (United Kingdom); Y Flomin, D Shcheglov (Ukraine).
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of
interest with respect to the research, authorship, and/or pub-
lication of this article: Diana Aguiar de Sousa, Rascha von
Martial, Thomas Gattringer, Adam Kobayashi, Miquel
Gallofre´, Franz Fazekas, Valery Feigin and Valeria Caso:
nothing to disclose.
So`nia Abilleira: Co-Principal Investigator of the
RACECAT trial (NCT02795962).
Istvan Szikora: First Past President of the European
Society of Minimally Invasive Neurological Therapy
(ESMINT), investigator in the TREVO Registry, consultant
to Medtronic Neurovascular, Stryker Neurovascular,
Codman Neurovascular and Sequent Medical, outside the
submitted work.
Urs Fischer: Secretary General of the European Stroke
Organisation. Received research grants from the Swiss
National Science Foundation and the Swiss Heart
Foundation. He is principal investigator of the SWITCH
26 European Stroke Journal 4(1)
trial, the ELAN trial and the SWIFT DIRECT trial.
Received consultancy for Medtronic/Covidien.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: This research received no specific grant from any
funding agency in the public, commercial, or not-for-
profit sectors.
Ethical approval
Not required.
Informed consent
The lead author (UF) affirms that this manuscript is an
honest, accurate and transparent account of the study being
reported; that no important aspects of the study have been
omitted; and that any discrepancies from the study as
planned have been explained. All authors, external and inter-
nal, had full access to all of the data (including statistical
reports and tables) in the study and can take responsibility
for the integrity of the data and the accuracy of the
data analysis.
Guarantor
Urs Fischer is the study guarantor.
Contributorship
Idea and concept: Urs Fischer, Valeria Caso.
Study design: Urs Fischer, Valeria Caso, Diana Aguiar de
Sousa, So`nia Abilleira, Thomas Gattringer, Adam
Kobayashi, Miquel Gallofre´, Franz Fazekas, Istvan Szikora.
Design of the questionnaire: Urs Fischer, Valeria Caso,
Diana Aguiar de Sousa, So`nia Abilleira, Thomas
Gattringer, Adam Kobayashi, Miquel Gallofre´, Franz
Fazekas, Istvan Szikora.
Literature search: Diana Aguiar de Sousa, Urs Fischer.
Figures: Diana Aguiar de Sousa.
Data collection: Rascha von Martial, Diana Aguiar de
Sousa, Valery Feigin, Urs Fischer.
Data analysis: Rascha von Martial, Diana Aguiar
de Sousa.
Data interpretation: Rascha von Martial, Diana Aguiar
de Sousa, Urs Fischer, So`nia Abilleira, Thomas Gattringer,
Adam Kobayashi, Miquel Gallofre´, Franz Fazekas,
Istvan Szikora.
Writing: Urs Fischer, Diana Aguiar de Sousa,
Valeria Caso.
Editorial comments: Susan Edith Kaplan.
Relevant intellectual inputs to the manuscript: So`nia
Abilleira, Rascha von Martial, Thomas Gattringer, Adam
Kobayashi, Miquel Gallofre´, Franz Fazekas, Istvan
Szikora, Valery Feigin.
Acknowledgements
We thank Bo Norrving, Didier Leys, Kennedy Lees, M and
Turgut Tatlisumak for their useful comments regarding the
questionnaire, data collection methodology and policy impli-
cations of this paper. We thank Susan Edith Kaplan for
editorial comments.
ORCID iD
Diana Aguiar de Sousa http://orcid.org/0000-0002-6702-
7924
So`nia Abilleira http://orcid.org/0000-0002-5587-128X
References
1. European Heart Network. European cardiovascular dis-
ease statistics. Brussels: European Heart Network, 2017.
2. Townsend N, Wilson L, Bhatnagar P, et al.
Cardiovascular disease in Europe: epidemiological
update 2016. Eur Heart J 2016; 37: 3232–3245.
3. Feigin VL, Lawes CM, Bennett DA, et al. Worldwide
stroke incidence and early case fatality reported in 56
population-based studies: a systematic review. Lancet
Neurol 2009; 8: 355–369.
4. Heuschmann PU, Wiedmann S, Wellwood I, et al. Three-
month stroke outcome: the European Registers of Stroke
(EROS) investigators. Neurology 2011; 76: 159–165.
5. Truelsen T, Piechowski-Jozwiak B, Bonita R, et al.
Stroke incidence and prevalence in Europe: a review of
available data. Eur J Neurol 2006; 13: 581–598.
6. Feigin VL, Norrving B and Mensah GA. Global burden
of stroke. Circ Res 2017; 120: 439–448.
7. GBD 2015 Mortality and Causes of Death
Collaborators. Global, regional, and national life expec-
tancy, all-cause mortality, and cause-specific mortality
for 249 causes of death, 1980–2015: a systematic analysis
for the Global Burden of Disease Study 2015. Lancet
2016; 388: 1459–1544.
8. Feigin VL, Roth GA, Naghavi M, et al. Global burden of
stroke and risk factors in 188 countries, during 1990–
2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet Neurol 2016; 15: 913–924.
9. Stevens E, Emmett E, Wang Y, et al. The burden of stroke
in Europe. London: Stroke Alliance for Europe, 2017.
10. Langhorne P, Williams BO, Gilchrist W, et al. Do stroke
units save lives? Lancet 1993; 342: 395–398.
11. Jørgensen HS, Nakayama H, Raaschou HO, et al. The
effect of a stroke unit: reductions in mortality, discharge
rate to nursing home, length of hospital stay, and cost.
Stroke 1995; 26: 1178–1182.
12. Indredavik B, Bakke F, Slordahl SA, et al. Stroke unit
treatment. 10-year follow-up. Stroke 1999; 30: 1524–1527.
13. Emberson J, Lees KR, Lyden P, et al. Effect of treatment
delay, age, and stroke severity on the effects of intrave-
nous thrombolysis with alteplase for acute ischaemic
stroke: a meta-analysis of individual patient data from
randomised trials. Lancet 2014; 384: 29–35.
14. Goyal M, Menon BK, van Zwam WH, et al.
Endovascular thrombectomy after large-vessel ischaemic
Aguiar de Sousa et al. 27
stroke: a meta-analysis of individual patient data from
five randomised trials. Lancet 2016; 387: 1723–1731.
15. Wahlgren N, Moreira T, Michel P, et al. ESO-KSU,
ESO, ESMINT, ESNR and EAN Mechanical thrombec-
tomy in acute ischemic stroke: consensus statement by
ESO-Karolinska Stroke Update 2014/2015, supported
by ESO, ESMINT, ESNR and EAN. Int J Stroke 2016;
11: 134–147.
16. Fiehler J, Cognard C, Gallitelli M, et al. European rec-
ommendations on organisation of interventional care in
acute stroke (EROICAS). Int J Stroke 2016; 11: 701–716.
17. United Nations, Department of Economic and Social
Affairs, Population Division World population pros-
pects: the 2015 revision – key findings and advance
tables. United Nations, New York, 2015.
18. Warlow C, Sudlow C, Dennis M, et al. Stroke. Lancet
2003; 362: 1211–1224.
19. Quoidbach V, Esposito G, Destrebecq F, et al. Policy
white paper towards optimizing research and care for
brain disorders. Brussels: European Brain Council, 2017.
20. Grotta JC and Hacke W. Stroke neurologist’s perspective
on the new endovascular trials. Stroke 2015; 46: 1447–1452.
21. Ringelstein EB, Mu¨ller-Jensen A, Nabavi DG, et al.
Comprehensive stroke unit. Nervenarzt 2011;
82: 778–784.
22. Lavine SD, Cockroft K, Hoh B, et al. Training guidelines
for endovascular stroke intervention: an international
multi-society consensus document. Intervent Neurol
2016; 5: 51–56.
23. McMeekin P, White P, Martin AJ, et al. Estimating the
number of UK stroke patients eligible for endovascular
thrombectomy. Eur Stroke J 2017; 2: 319–326.
24. Kjellstr€om T, Norrving B and Shatchkute A.
Helsingborg declaration 2006 on European stroke strat-
egies. Cerebrovasc Dis 2007; 23: 231–241.
28 European Stroke Journal 4(1)
